Key Points
- Insider sale: Septerna insider Samira Shaikhly sold 11,798 shares on May 26 at an average price of $30.06, totaling about $354,648. After the sale, she retained 793 shares, a 93.7% drop in her holdings.
- Recent company performance: Septerna reported quarterly EPS of ($0.19), beating estimates, and revenue of $26.52 million, well above expectations. The stock was trading up 4.2% and opened at $31.05, near its 12-month high of $32.63.
- Analyst and investor sentiment: Wall Street remains broadly positive, with a consensus rating of Moderate Buy and an average price target of $43.13. Large institutional holders such as Goldman Sachs, Vanguard, and Avoro have also increased or maintained significant positions.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) insider Samira Shaikhly sold 11,798 shares of Septerna stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total value of $354,647.88. Following the completion of the transaction, the insider directly owned 793 shares in the company, valued at $23,837.58. This trade represents a 93.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Samira Shaikhly also recently made the following trade(s):
- On Monday, March 2nd, Samira Shaikhly sold 70,453 shares of Septerna stock. The shares were sold at an average price of $28.10, for a total transaction of $1,979,729.30.
Septerna Trading Up 4.2%
Shares of NASDAQ:SEPN opened at $31.05 on Friday. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -38.33 and a beta of 2.21. The company has a 50-day moving average price of $25.36 and a 200-day moving average price of $26.06. Septerna, Inc. has a 12 month low of $9.11 and a 12 month high of $32.63.
Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The firm had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, research analysts forecast that Septerna, Inc. will post -1.57 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently weighed in on SEPN shares. JPMorgan Chase & Co. lifted their price target on Septerna from $34.00 to $38.00 and gave the company an "overweight" rating in a research report on Tuesday, March 24th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $60.00 target price on shares of Septerna in a research note on Tuesday, March 10th. Stifel Nicolaus began coverage on shares of Septerna in a research report on Friday, May 1st. They set a "buy" rating and a $43.00 price target for the company. Wells Fargo & Company upped their price target on Septerna from $28.00 to $48.00 and gave the company an "overweight" rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Septerna in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Septerna has a consensus rating of "Moderate Buy" and an average price target of $43.13.
View Our Latest Analysis on Septerna
Institutional Investors Weigh In On Septerna
A number of large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its position in Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company's stock worth $75,698,000 after purchasing an additional 1,260,409 shares during the period. Vanguard Group Inc. increased its holdings in Septerna by 7.4% during the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company's stock valued at $28,568,000 after buying an additional 104,394 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Septerna by 8.1% during the 3rd quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company's stock worth $25,158,000 after acquiring an additional 100,000 shares during the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Septerna by 38.9% during the 3rd quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company's stock worth $22,130,000 after acquiring an additional 329,264 shares during the last quarter. Finally, Janus Henderson Group PLC purchased a new position in shares of Septerna during the 1st quarter worth $21,334,000.
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
